Latest / AI Investment Edge: Stocks, Markets & Money / Medtronic: A Smaller Company. A Stronger Investment? | EP027
Transcript
- 0:00SPEAKER_01: You know,
- 0:00SPEAKER_01: usually when a massive corporation spins off a division,
- 0:04SPEAKER_01: the playbook is just, well, it's pretty standard.
- 0:06SPEAKER_00: Right.
- 0:06SPEAKER_00: You just sell the piece that doesn't fit and you pocket the cash.
- 0:08SPEAKER_01: Exactly.
- 0:09SPEAKER_01: You pocket billions and hopefully you reinvest it somewhere smarter.
- 0:13SPEAKER_01: But Medtronic just did something entirely different with their diabetes business.
- 0:17SPEAKER_00: Oh, definitely.
- 0:18SPEAKER_01: Instead of selling it for cash,
- 0:19SPEAKER_01: they basically traded the remaining stake in it for their own shares.
- 0:23SPEAKER_01: It's a really fascinating move.
- 0:24SPEAKER_01: And it sets up this...
- 0:25SPEAKER_01: Central mystery for us today,
- 0:27SPEAKER_01: like can a leaner,
- 0:28SPEAKER_01: more focused medical device company actually turn growing hospital procedure rates
- 0:33SPEAKER_01: into real returns for investors?
- 0:35SPEAKER_00: That's the million dollar question.
- 0:37SPEAKER_01: Yeah.
- 0:37SPEAKER_01: So welcome to this deep dive on AI Investment Edge, episode 27.
- 0:42SPEAKER_00: It's really the perfect test case for how modern corporate strategy actually hits
- 0:46SPEAKER_00: the balance sheet.
- 0:47SPEAKER_00: And just to set our baseline right away,
- 0:49SPEAKER_00: the actual September released model labels were a buy for both the one year
- 0:54SPEAKER_00: and five year horizons.
- 0:55SPEAKER_01: Okay, a buy for both.
- 0:57SPEAKER_00: Yes, but we need to be very precise here.
- 0:59SPEAKER_00: Those views, they are based on the original September reference price.
- 1:02SPEAKER_01: Right.
- 1:03SPEAKER_00: These are dated model assessments,
- 1:05SPEAKER_00: and they're looking out to the third quarter of 2027 and the third quarter of 2031.
- 1:10SPEAKER_01: Got it.
- 1:11SPEAKER_01: So we aren't looking at like a fresh October rescore today.
- 1:14SPEAKER_00: No, exactly.
- 1:15SPEAKER_00: We are stress testing the underlying business fundamentals to see if
- 1:19SPEAKER_00: that original conditional view still holds water.
- 1:23SPEAKER_01: And I guess to understand if this leaner version of Medtronic works,
- 1:26SPEAKER_01: you really have to know what they are stripping down to, right?
- 1:29SPEAKER_01: Absolutely.
- 1:30SPEAKER_01: Because this is an absolute giant in hospital medical tech.
- 1:33SPEAKER_01: We are talking about life-saving hardware,
- 1:35SPEAKER_01: pacemakers like the Micra,
- 1:38SPEAKER_01: Evolute heart valves, ablation catheters, and major robotic systems like Hugo.
- 1:43SPEAKER_00: Yeah, it is a very hardware-heavy operation.
- 1:45SPEAKER_01: Right.
- 1:46SPEAKER_01: But building great hardware is really only step one.
- 1:49SPEAKER_00: Exactly.
- 1:50SPEAKER_00: I mean, the revenue model relies on selling the initial capital equipment,
- 1:54SPEAKER_00: getting those implants into patients,
- 1:56SPEAKER_00: and then,
- 1:57SPEAKER_00: and this is key,
- 1:59SPEAKER_00: securing that recurring revenue from disposable instruments
- 2:02SPEAKER_00: during repeat procedures.
- 2:04SPEAKER_01: But none of that happens in a vacuum.
- 2:06SPEAKER_00: No, it doesn't.
- 2:07SPEAKER_00: It depends on doctors actually adopting the tech,
- 2:09SPEAKER_00: regulators approving it,
- 2:11SPEAKER_00: and insurance companies actually deciding it's worth reimbursing.
- 2:15SPEAKER_01: Which brings us back to the separation that completed on October 15th.
- 2:19SPEAKER_00: Right, the split.
- 2:20SPEAKER_01: Yeah, they split off the mini-med diabetes business.
- 2:23SPEAKER_01: But the actual mechanics of how they did it are so crucial.
- 2:27SPEAKER_01: This wasn't a cash sale, right?
- 2:29SPEAKER_01: And it wasn't an automatic free distribution of shares to everyone holding Medtronic stock.
- 2:34SPEAKER_00: No, it was an exchange.
- 2:35SPEAKER_01: Exactly.
- 2:36SPEAKER_01: Participating shareholders essentially exchanged their Medtronic parent shares
- 2:40SPEAKER_01: for mini-med shares.
- 2:41SPEAKER_00: Right.
- 2:41SPEAKER_00: So it's essentially like a stock buyback.
- 2:44SPEAKER_00: But instead of spending actual cash,
- 2:46SPEAKER_00: Medtronic used the diabetes business as currency to retire their own parent shares.
- 2:51SPEAKER_01: Which means mathematically fewer slices of the pie should make
- 2:54SPEAKER_01: the remaining slices more valuable, right?
- 2:56SPEAKER_00: Well, on paper, yes.
- 2:58SPEAKER_00: That share count reduction is a clear tailwind for per share metrics.
- 3:02SPEAKER_00: But the operational reality is a lot more complex.
- 3:06SPEAKER_01: Because of the lost revenue?
- 3:07SPEAKER_00: Exactly.
- 3:08SPEAKER_00: By shedding MiniMed, they also removed all the earnings that the diabetes business generated.
- 3:14SPEAKER_00: And on top of that,
- 3:15SPEAKER_00: breaking apart a massive corporate infrastructure like
- 3:17SPEAKER_00: that involves significant transition costs.
- 3:20SPEAKER_01: Oh, for sure.
- 3:21SPEAKER_00: So the benefit of having fewer outstanding shares is immediately offset
- 3:25SPEAKER_00: by those lost earnings and the sheer friction of the split.
- 3:28SPEAKER_01: It's like downsizing from a mansion to a smaller house to save on property taxes,
- 3:33SPEAKER_01: but then you spend all your savings on the moving company,
- 3:35SPEAKER_01: the real estate agent, and all new furniture.
- 3:37SPEAKER_00: That's a great way to put it.
- 3:39SPEAKER_01: The long-term math might work out, but the upfront friction is just brutal.
- 3:43SPEAKER_01: So let's look at the financial reality of this newly focused company,
- 3:47SPEAKER_01: starting with their top line.
- 3:49SPEAKER_00: Okay, let's do it.
- 3:50SPEAKER_01: So if you're looking at their first quarter of fiscal year 2027,
- 3:54SPEAKER_01: which ended July 31st,
- 3:55SPEAKER_01: they reported about $9.8 billion in revenue and 13.7% organic growth.
- 4:01SPEAKER_00: Right.
- 4:02SPEAKER_01: For a legacy hardware company,
- 4:03SPEAKER_01: 14% growth sounds like a rocket ship, but there's a massive asterisk there.
- 4:08SPEAKER_00: Oh, yeah.
- 4:09SPEAKER_00: The extra selling week.
- 4:10SPEAKER_01: Right.
- 4:12SPEAKER_01: They had an extra week in that quarter,
- 4:14SPEAKER_01: which artificially pumped about $570 million into that top line.
- 4:19SPEAKER_01: It's like a retail store bragging about record weekly sales,
- 4:22SPEAKER_01: but they were actually open for eight days instead of seven.
- 4:25SPEAKER_01: It totally distorts the picture.
- 4:26SPEAKER_00: It really does.
- 4:28SPEAKER_00: And when you adjust for that and look at an ordinary week estimate, the growth is roughly 7%.
- 4:33SPEAKER_01: Okay, 7%.
- 4:34SPEAKER_00: Now, 7% is still a very solid number for a company of this scale,
- 4:38SPEAKER_00: but it requires a totally different valuation mindset than
- 4:41SPEAKER_00: a sustainable 14% run rate.
- 4:43SPEAKER_01: Right, because the real test is what happens when we get back to normal length quarters.
- 4:48SPEAKER_00: Exactly.
- 4:48SPEAKER_01: And, you know,
- 4:49SPEAKER_01: revenue is just vanity if you don't keep the cash,
- 4:51SPEAKER_01: which takes us right into profitability.
- 4:54SPEAKER_01: Looking at fiscal year 2026, their GAAP operating margin was basically flat at 17.8%.
- 4:59SPEAKER_01: Right.
- 5:00SPEAKER_00: Very flat.
- 5:01SPEAKER_01: And in this recent Q1 of 2027, that GAAP margin ticked up just slightly to 18.1%.
- 5:06SPEAKER_01: Right.
- 5:07SPEAKER_01: And just to translate for anyone not staring at an accounting textbook right now,
- 5:11SPEAKER_01: GAAP stands for Generally Accepted Accounting Principles.
- 5:14SPEAKER_00: It's the strict, unvarnished reality.
- 5:16SPEAKER_00: Right.
- 5:17SPEAKER_01: Exactly.
- 5:18SPEAKER_01: Which is distinct from the adjusted margin they like to highlight, which sits around 24%.
- 5:23SPEAKER_01: But either way, maintaining those margins is an uphill battle right now.
- 5:27SPEAKER_00: Well, the broader environment for medical devices is just incredibly tight.
- 5:31SPEAKER_01: Yeah.
- 5:31SPEAKER_00: I mean, yes,
- 5:32SPEAKER_00: a better mix of highly profitable procedures and
- 5:35SPEAKER_00: a simpler corporate structure can help expand margins.
- 5:38SPEAKER_00: But they are operating in a post-COVID reality
- 5:40SPEAKER_00: where hospital procurement boards are aggressively fighting for every single dollar.
- 5:45SPEAKER_01: Oh, absolutely.
- 5:45SPEAKER_01: Yeah.
- 5:46SPEAKER_00: And you add in tariffs and those internal transition costs we just talked about.
- 5:50SPEAKER_00: And that margin expansion is something they have to violently defend every single quarter.
- 5:55SPEAKER_01: Right.
- 5:55SPEAKER_01: So if you're a listener holding this stock,
- 5:57SPEAKER_01: you're probably looking at the balance sheet for some comfort.
- 6:00SPEAKER_00: You'd hope so.
- 6:01SPEAKER_01: Pre-separation at the end of July,
- 6:03SPEAKER_01: they were sitting on about $8.8 billion in cash and investments.
- 6:07SPEAKER_00: Okay.
- 6:07SPEAKER_01: But you have to weigh that against roughly $28 billion in combined debt.
- 6:11SPEAKER_00: Yeah, that's a lot of leverage.
- 6:12SPEAKER_01: It is.
- 6:13SPEAKER_01: And that leverage,
- 6:14SPEAKER_01: combined with all the intangible assets sitting on their books
- 6:17SPEAKER_01: from past acquisitions, means their financial flexibility really has limits.
- 6:22SPEAKER_01: It makes the safety of their dividend conditional on them executing perfectly.
- 6:26SPEAKER_01: It's not an absolute guarantee.
- 6:27SPEAKER_00: Which is exactly why we have to scrutinize their capital allocation.
- 6:31SPEAKER_00: We need to see exactly where the cash is going.
- 6:33SPEAKER_01: Right.
- 6:34SPEAKER_00: So in fiscal year 2026, they spent about $1.9 billion on property and equipment additions.
- 6:40SPEAKER_01: Okay.
- 6:41SPEAKER_00: That's roughly 5.2% of their sales.
- 6:43SPEAKER_01: But you know that $1.9 billion doesn't really tell us the whole story, does it?
- 6:47SPEAKER_00: No, it doesn't.
- 6:48SPEAKER_01: Because we don't have the breakdown of how much of that is just basic maintenance,
- 6:51SPEAKER_01: like keeping the lights on, versus actual growth spending.
- 6:54SPEAKER_01: Plus, research and acquisitions are entirely extra.
- 6:57SPEAKER_00: Oh, absolutely.
- 6:58SPEAKER_01: Just look at September.
- 6:59SPEAKER_01: They announced an investment in Cornerstone Robotics for roughly $700 million.
- 7:04SPEAKER_01: And that was paid out in Q2 of fiscal 2027.
- 7:08SPEAKER_01: So the cash is just flowing out in multiple directions.
- 7:11SPEAKER_01: Let's actually trace that cash bridge.
- 7:13SPEAKER_00: Okay.
- 7:14SPEAKER_00: We can trace it clearly for fiscal year 2026.
- 7:17SPEAKER_00: You start with about $7.3 billion in operating cash flow.
- 7:21SPEAKER_00: And you subtract that $1.9 billion for the property and equipment additions.
- 7:25SPEAKER_00: And you arrive at a company to find free cash flow of about $5.4 billion.
- 7:30SPEAKER_01: Okay, so $5.4 billion sounds massive in a vacuum.
- 7:33SPEAKER_01: Sure does.
- 7:34SPEAKER_01: But I'm looking at their historical free cash flow,
- 7:36SPEAKER_01: and back in fiscal 2022, they were pulling in about $6 billion.
- 7:40SPEAKER_01: Right.
- 7:41SPEAKER_01: Then it dropped to $4.6 billion in 2023,
- 7:43SPEAKER_01: hovered around $5.2 billion through 2024 and 2025, and now we are at $5.4 billion.
- 7:45SPEAKER_01: Yeah.
- 7:51SPEAKER_01: It looks less like uninterrupted compounding growth
- 7:54SPEAKER_01: and more like they are just slowly trying to recover lost ground.
- 7:58SPEAKER_00: That historical context is so vital,
- 8:00SPEAKER_00: especially because those past figures still include the diabetes business
- 8:03SPEAKER_00: that they just separated.
- 8:05SPEAKER_01: Oh, right.
- 8:05SPEAKER_01: Good point.
- 8:06SPEAKER_00: So when we transition from this historical cash generation
- 8:10SPEAKER_00: to projecting future value,
- 8:13SPEAKER_00: the market is effectively pricing in whether that recovery can accelerate without
- 8:17SPEAKER_00: the mini-med division.
- 8:18SPEAKER_01: Let's map out what that means for the actual stock price.
- 8:20SPEAKER_01: Where are we setting the baseline?
- 8:22SPEAKER_00: We are referencing the last available Alpaca IEX trade from October 20th,
- 8:27SPEAKER_00: which was sitting at about $95.
- 8:31SPEAKER_00: And for clarity,
- 8:31SPEAKER_00: that's an intraday snapshot from an alternative exchange,
- 8:34SPEAKER_00: not a certified consolidated close.
- 8:38SPEAKER_00: But using that $95 base,
- 8:41SPEAKER_00: the evidence-weighted targets place the stock at roughly $102 by the third quarter
- 8:44SPEAKER_00: of 2027,
- 8:48SPEAKER_00: And $145 by the third quarter of 2031.
- 8:50SPEAKER_00: Okay.
- 8:51SPEAKER_01: So translating that into returns from the $95 reference,
- 8:55SPEAKER_01: we are looking at cumulative price gains of about 7.6% for that near horizon and 53%
- 9:02SPEAKER_01: for the longer one.
- 9:03SPEAKER_00: Correct.
- 9:04SPEAKER_01: And it's really worth pointing out that the first horizon is now less than a year away.
- 9:08SPEAKER_00: Right.
- 9:09SPEAKER_00: And we cannot ignore the dividend component here.
- 9:11SPEAKER_01: Definitely not.
- 9:12SPEAKER_00: The latest $0.72 quarterly dividend was paid on October 16th.
- 9:16SPEAKER_00: So that is already in the past.
- 9:18SPEAKER_00: But if we assume a flat $0.72 going forward.
- 9:21SPEAKER_01: Which is roughly $2.9 annually.
- 9:24SPEAKER_00: Exactly.
- 9:25SPEAKER_00: The math becomes very interesting.
- 9:27SPEAKER_00: Before the third quarter of 2027 horizon,
- 9:30SPEAKER_00: there are three future payments, adding about $2.2 in cash per share.
- 9:35SPEAKER_01: Okay.
- 9:36SPEAKER_00: And before the 2031 horizon, there are 19 payments, which adds about $13.7 in cash.
- 9:43SPEAKER_01: Wow.
- 9:43SPEAKER_01: So if you aren't reinvesting those dividends,
- 9:45SPEAKER_01: and we look at this expressly before tax and fees,
- 9:48SPEAKER_01: those gross cash-inclusive returns jumped to 9.9% for 2027 and 67% for 2031.
- 9:56SPEAKER_00: Right.
- 9:56SPEAKER_00: Those are the base targets.
- 9:57SPEAKER_00: But to understand the true risk profile, we have to look at the qualitative extremes.
- 10:01SPEAKER_01: The best and worst case scenarios?
- 10:03SPEAKER_00: Exactly.
- 10:03SPEAKER_00: The scenarios where things go exceptionally right or horribly wrong.
- 10:08SPEAKER_00: Now, the numerical endpoints for these aren't locked in, but the drivers are really clear.
- 10:13SPEAKER_01: Okay, what's the bull case?
- 10:15SPEAKER_00: In a qualitative bull case,
- 10:16SPEAKER_00: you would see a much faster adoption of their recurring technologies,
- 10:20SPEAKER_00: like the ablation catheters.
- 10:22SPEAKER_00: And they would manage to squeeze much better margins out of the continuing business,
- 10:26SPEAKER_00: easily beating those gradual assumptions.
- 10:28SPEAKER_01: And the bear case?
- 10:30SPEAKER_00: In a qualitative bear case,
- 10:31SPEAKER_00: hospital pricing pressure,
- 10:33SPEAKER_00: sluggish uptake of their surgical robotics,
- 10:35SPEAKER_00: and those lingering transition costs just completely overwhelm
- 10:38SPEAKER_00: the mathematical benefit of the smaller share count.
- 10:41SPEAKER_01: So if you're an investor trying to figure out which way this will swing,
- 10:44SPEAKER_01: you really have to watch the four quadrants of their business.
- 10:47SPEAKER_00: Yes, absolutely.
- 10:49SPEAKER_01: The core drivers pushing them forward are overall procedural demand and
- 10:52SPEAKER_01: the wider adoption of their ablation tech.
- 10:55SPEAKER_00: Right.
- 10:55SPEAKER_01: But the core fictions pushing back are rival device platforms fighting for
- 10:59SPEAKER_01: the same contracts,
- 11:01SPEAKER_01: tight hospital equipment budgets,
- 11:02SPEAKER_01: and just the plain execution costs of running a leaner ship.
- 11:06SPEAKER_00: While the real volatility, however, lives in the tails.
- 11:09SPEAKER_01: Oh, for sure.
- 11:10SPEAKER_00: On the upside tail,
- 11:11SPEAKER_00: a massive catalyst would be securing additional indications for
- 11:15SPEAKER_00: the Hugo robotic system that actually lead to hospitals utilizing more instruments.
- 11:19SPEAKER_01: Yeah.
- 11:20SPEAKER_00: Another major conditional upside is securing broader reimbursement for renal denervation.
- 11:26SPEAKER_01: Actually,
- 11:26SPEAKER_01: let me pause on that renal denervation thing for a second because
- 11:29SPEAKER_01: the mechanism there is fascinating and easily misunderstood.
- 11:33SPEAKER_00: It really is.
- 11:33SPEAKER_01: It's a procedure designed to lower blood pressure in selected patients,
- 11:37SPEAKER_01: but it uses catheter-delivered energy to disrupt sympathetic nerves around
- 11:42SPEAKER_01: the renal arteries.
- 11:43SPEAKER_00: Right.
- 11:43SPEAKER_00: Not inside the kidneys.
- 11:44SPEAKER_01: Exactly.
- 11:45SPEAKER_01: It is not destroying kidney tissue or nerves inside the kidneys.
- 11:49SPEAKER_01: It's like carefully cutting the communication wire on the outside of a building
- 11:53SPEAKER_01: to quiet a blaring alarm rather than smashing the alarm box inside the building.
- 11:57SPEAKER_00: That's a really good analogy.
- 11:59SPEAKER_01: The safety profile is just entirely different because of that distinction.
- 12:02SPEAKER_00: And that distinction is critical for regulatory and clinical trust.
- 12:06SPEAKER_00: It highlights why regulatory approval,
- 12:08SPEAKER_00: insurance coverage, and actual hospital use are three completely distinct hurdles.
- 12:12SPEAKER_00: Right.
- 12:13SPEAKER_00: That upside remains conditional until all three are cleared.
- 12:17SPEAKER_00: Now, on the downside tail, the massive risks are pretty binary.
- 12:21SPEAKER_01: Like what?
- 12:22SPEAKER_00: A major device safety failure, a widespread recall, or a severe reimbursement reset.
- 12:28SPEAKER_01: Oh, wow.
- 12:28SPEAKER_01: Yeah.
- 12:29SPEAKER_00: Even if underlying procedure volumes are growing perfectly,
- 12:32SPEAKER_00: a statutory price shock from insurers or governments can decimate their margins.
- 12:37SPEAKER_01: So with all these moving parts,
- 12:39SPEAKER_01: the extra selling weeks,
- 12:41SPEAKER_01: the margin pressures, the new technologies, where is the alpha gap?
- 12:45SPEAKER_00: That's the question.
- 12:46SPEAKER_01: If you are analyzing this, where is the broader market getting the story wrong?
- 12:52SPEAKER_00: The internal research gap hinges on two opposing mistakes.
- 12:55SPEAKER_00: Okay.
- 13:07SPEAKER_00: Right.
- 13:08SPEAKER_01: Dismissing the good news.
- 13:09SPEAKER_00: Exactly.
- 13:10SPEAKER_00: The opposing mistake is blind optimism.
- 13:13SPEAKER_00: Are investors paying a premium valuation for the illusion of uninterrupted growth
- 13:17SPEAKER_00: and effortless margin expansion,
- 13:19SPEAKER_00: completely ignoring the reality of hospital budgets?
- 13:22SPEAKER_01: Yeah, that makes sense.
- 13:23SPEAKER_00: The investable test
- 13:24SPEAKER_00: to solve this is measuring ordinary length growth plus cash generation per remaining
- 13:29SPEAKER_00: share, specifically using comparable reporting for the continuing business.
- 13:34SPEAKER_01: So how did the AI models actually process that conflict?
- 13:38SPEAKER_01: Because I know there's a very specific setup behind these projections.
- 13:41SPEAKER_00: Oh, absolutely.
- 13:42SPEAKER_00: The September panel is comprehensive.
- 13:44SPEAKER_00: It consists of 14 AI research contributions,
- 13:47SPEAKER_00: analyzing the data across nine framework perspectives,
- 13:51SPEAKER_00: utilizing three distinct model versions.
- 13:53SPEAKER_01: Okay.
- 13:54SPEAKER_00: And 12 of those contributions actually share the same model release.
- 13:58SPEAKER_01: And just to clarify for the listener,
- 14:00SPEAKER_01: we are talking about disagreement among correlated AI perspectives here, right?
- 14:04SPEAKER_01: Yes.
- 14:05SPEAKER_01: This is based on research credibility weights.
- 14:07SPEAKER_01: This is not like a survey of human Wall Street analysts throwing out event probabilities.
- 14:12SPEAKER_00: That is exactly right.
- 14:13SPEAKER_00: The models that lean toward growth are favoring a pipeline driven revaluation of the stock.
- 14:19SPEAKER_00: They really see the new tech paying off.
- 14:20SPEAKER_00: Right.
- 14:21SPEAKER_00: But the more skeptical AI models are heavily emphasizing the friction,
- 14:26SPEAKER_00: the realities of hospital budgets,
- 14:28SPEAKER_00: the fierce competition, and the execution risk of the separation.
- 14:33SPEAKER_00: The evidence weights aggregate the credibility of those research perspectives.
- 14:36SPEAKER_00: They do not assign numerical probabilities to specific events.
- 14:41SPEAKER_01: So as these models project forward, what are the actual windows we should be watching?
- 14:46SPEAKER_00: Well,
- 14:47SPEAKER_00: the models track scenario checkpoints through the fourth quarter of 2026 and then
- 14:51SPEAKER_00: the first, second and third quarters of 2027.
- 14:53SPEAKER_00: Okay.
- 14:54SPEAKER_00: But it is vital to remember that these are model windows.
- 14:58SPEAKER_00: They are not scheduled, confirmed company events or guaranteed earnings dates.
- 15:02SPEAKER_01: Right.
- 15:02SPEAKER_01: Of course.
- 15:03SPEAKER_00: You have to watch the actual quarterly results to see the ordinary length sales,
- 15:08SPEAKER_00: the real margins and the actual transition costs.
- 15:11SPEAKER_01: You know,
- 15:12SPEAKER_01: it strikes me that the completion of this separation in October is
- 15:15SPEAKER_01: a massive fundamental change from the research batches we were looking at back
- 15:19SPEAKER_01: in July and September.
- 15:21SPEAKER_00: Oh, completely.
- 15:22SPEAKER_01: Back then,
- 15:22SPEAKER_01: the focus was mostly on whether the demographic demand was resilient and adjusting
- 15:27SPEAKER_01: for that extra week.
- 15:28SPEAKER_01: Now, what was just a proposed corporate action is a completed reality.
- 15:33SPEAKER_00: It fundamentally changes the structure, yes.
- 15:35SPEAKER_01: But completing a separation does not automatically guarantee better earnings.
- 15:39SPEAKER_00: No, definitely not.
- 15:41SPEAKER_00: To really grasp what Medtronic needs to prove,
- 15:44SPEAKER_00: it helps to revisit a few of our previous deep dives.
- 15:46SPEAKER_01: Oh, good idea.
- 15:48SPEAKER_00: Our Boston Scientific conversation serves as the perfect benchmark for understanding
- 15:52SPEAKER_00: the intense competition in ablation and how those procedures actually convert
- 15:57SPEAKER_00: into profit.
- 15:58SPEAKER_01: Right.
- 15:59SPEAKER_00: And our Novo Nordisk conversation provides essential context on
- 16:01SPEAKER_00: the pharmaceutical side,
- 16:03SPEAKER_00: demonstrating that the rise of weight loss drugs doesn't necessarily eliminate
- 16:07SPEAKER_00: the demand for structural medical devices.
- 16:09SPEAKER_00: Right.
- 16:09SPEAKER_01: And I'd add our Northrop Grumman conversation to that list, too.
- 16:12SPEAKER_00: Oh, absolutely.
- 16:13SPEAKER_01: That episode set the baseline for how a massive multi-year order book actually turns into cash.
- 16:19SPEAKER_01: Obviously,
- 16:19SPEAKER_01: a hospital buying a fleet of surgical robots is very different from
- 16:23SPEAKER_01: the government buying defense systems.
- 16:25SPEAKER_00: Sure.
- 16:26SPEAKER_01: But Medtronic faces that exact same parallel test.
- 16:29SPEAKER_01: Can you efficiently convert complex hardware orders into actual free cash flow?
- 16:34SPEAKER_00: That is the ultimate test.
- 16:36SPEAKER_00: Which brings us to risk management.
- 16:39SPEAKER_00: What invalidates this entire thesis?
- 16:41SPEAKER_01: Right.
- 16:42SPEAKER_01: What are the specific triggers that prove this conditional view wrong?
- 16:46SPEAKER_00: You have to reassess immediately if repeated normal length quarters show
- 16:51SPEAKER_00: that procedural growth is failing.
- 16:53SPEAKER_01: Okay.
- 16:54SPEAKER_00: Or if pricing pressure
- 16:55SPEAKER_00: from hospitals starts eroding their margins despite high procedural volume.
- 17:00SPEAKER_00: Or if the cost of the separation completely wipe out any per share progress.
- 17:04SPEAKER_01: That makes sense.
- 17:06SPEAKER_00: Most crucially,
- 17:06SPEAKER_00: if free cash flow stops covering the dividend and the essential investments
- 17:11SPEAKER_00: in their pipeline, the thesis just breaks.
- 17:14SPEAKER_00: Retiring shares cannot mask underlying operational failure.
- 17:18SPEAKER_00: And naturally, any major product setback or safety recall warrants a fast reset of expectations.
- 17:25SPEAKER_01: So let's pull all of this together.
- 17:27SPEAKER_01: The dated September models say buy at both the one-year and five-year horizons.
- 17:32SPEAKER_00: Yes.
- 17:33SPEAKER_01: The conditional thesis today is that a leaner,
- 17:35SPEAKER_01: more focused Medtronic can indeed compound cash without needing to be priced like
- 17:40SPEAKER_01: a hyper growth tech stock for the math to work.
- 17:43SPEAKER_01: But the entire burden of proof rests on their post separation economics
- 17:48SPEAKER_01: and their performance in standard ordinary length quarters.
- 17:51SPEAKER_00: The structural benefits are there, but execution is everything.
- 17:55SPEAKER_01: That's exactly what we started with.
- 17:57SPEAKER_01: They traded away a piece of themselves to get leaner,
- 17:59SPEAKER_01: but being leaner only matters if it helps you run faster.
- 18:03SPEAKER_00: Exactly.
- 18:04SPEAKER_01: Which leaves me with one final thought for you to ponder.
- 18:06SPEAKER_01: If software,
- 18:07SPEAKER_01: data and AI become the most critical,
- 18:09SPEAKER_01: high margin parts of hospital practice in the future,
- 18:12SPEAKER_01: can a hardware heavy legacy company like Medtronic capture that value?
- 18:17SPEAKER_01: Or are they destined to just be the dependable plumbing of the medical world?
- 18:20SPEAKER_00: That is really the defining question for their next decade of growth.
- 18:24SPEAKER_01: We highly encourage you to explore the linked Medtronic Consensus page to see
- 18:28SPEAKER_01: the exact calculations and AI weights for yourself.
- 18:31SPEAKER_01: And definitely go back and listen to our Boston Scientific,
- 18:33SPEAKER_01: Novo Nordisk,
- 18:34SPEAKER_01: and Northrop Grumman conversations to see how all these industry threads connect.
- 18:38SPEAKER_00: Definitely check those out.
- 18:39SPEAKER_01: Be sure to follow or subscribe for our future research.
- 18:42SPEAKER_01: You will not want to miss our upcoming deep dive into Adyen,
- 18:45SPEAKER_01: where we'll be posing a really fascinating curiosity.
- 18:48SPEAKER_01: When global payment volumes grow exponentially,
- 18:50SPEAKER_01: how much of that actually becomes durable platform profit?
- 18:54SPEAKER_01: Thanks for joining us and we'll catch you next time.